Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Apellis Pharmaceuticals Inc (APLS)
NASDAQ:APLS
RESEARCH TOOLSreports
Apellis Pharmaceuticals (APLS) Stock Price & Analysis
759 Followers
APLS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$19.83 - $73.80
Previous Close$37.98
Volume151.06K
Average Volume (3M)1.47M
Market Cap
$4.54B
Enterprise Value$4.39B
Total Cash (Recent Filing)$325.90M
Total Debt (Recent Filing)$109.14M
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Aug 01, 2024EPS Estimate
-$0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.46
Shares Outstanding121,365,555
10 Day Avg. Volume1,122,999
30 Day Avg. Volume1,472,501
Standard Deviation0.22
R-Squared0.05
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)17.33
Price to Sales (P/S)31.57
Price to Cash Flow (P/CF)-8.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.47
Enterprise Value/Gross Profit12.99
Enterprise Value/Ebitda-11.38
Forecast
1Y Price Target
$72.58Price Target Upside94.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Apellis Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceStrong Syfovre sales in 1Q24, with revenues of $137.5M, topping consensus of $129M.
Market DemandThe company continues to see double-digit account growth per week since Syfovre's launch, underscoring meaningful demand.
Market ShareAPLS claimed 85% market share for Syfovre, based on the number of GA patients treated.
Bears Say
Clinical BenefitsThere have yet to be data convincingly demonstrating Syfovre use leading to clear, clinically meaningful functional benefit.
Market CompetitionA loss of Syfovre's market share leadership within just one year's time.
Regulatory ApprovalShares of APLS are trading down following the announcement of a negative opinion by the European Medicines Agency on potential European regulatory approval for pegcetacoplan.
---
Ownership Overview
14.93% Insiders
37.33% Mutual Funds
14.91% Other Institutional Investors
32.83% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
APLS FAQ
What was Apellis Pharmaceuticals Inc’s price range in the past 12 months?
Apellis Pharmaceuticals Inc lowest stock price was $19.83 and its highest was $73.80 in the past 12 months.
What is Apellis Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Apellis Pharmaceuticals Inc’s upcoming earnings report date?
Apellis Pharmaceuticals Inc’s upcoming earnings report date is Aug 01, 2024 which is in 10 days.
How were Apellis Pharmaceuticals Inc’s earnings last quarter?
Apellis Pharmaceuticals Inc released its earnings results on May 07, 2024. The company reported -$0.54 earnings per share for the quarter, missing the consensus estimate of -$0.477 by -$0.063.
Is Apellis Pharmaceuticals Inc overvalued?
According to Wall Street analysts Apellis Pharmaceuticals Inc’s price is currently Undervalued.
Does Apellis Pharmaceuticals Inc pay dividends?
Apellis Pharmaceuticals Inc does not currently pay dividends.
What is Apellis Pharmaceuticals Inc’s EPS estimate?
Apellis Pharmaceuticals Inc’s EPS estimate is -$0.28.
How many shares outstanding does Apellis Pharmaceuticals Inc have?
Apellis Pharmaceuticals Inc has 121,365,555 shares outstanding.
What happened to Apellis Pharmaceuticals Inc’s price movement after its last earnings report?
Apellis Pharmaceuticals Inc reported an EPS of -$0.54 in its last earnings report, missing expectations of -$0.477. Following the earnings report the stock price went down -10.059%.
Which hedge fund is a major shareholder of Apellis Pharmaceuticals Inc?
Among the largest hedge funds holding Apellis Pharmaceuticals Inc’s share is Iron Triangle Partners LP. It holds Apellis Pharmaceuticals Inc’s shares valued at 32M.
---
Apellis Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$72.58 (94.22% Upside)
$72.58 (94.22% Upside)
Blogger Sentiment
Bullish
APLS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 588.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.19%
12-Months-Change
Fundamentals
Return on Equity
-122.94%
Trailing 12-Months
Asset Growth
-15.01%
Trailing 12-Months
Company Description
Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
---
APLS Company Deck
---
APLS Earnings Call
Q1 2024
0:00 / 0:00
---
APLS Stock 12 Month Forecast
Average Price Target
$72.58
▲(94.22% Upside)
Technical Analysis
Best Analysts Covering APLS
1 Year
1 Year Success Rate
17/30 ratings generated profit
1 Year Average Return
+13.57%
reiterated a buy rating 21 days ago
Copying Justin Kim's trades and holding each position for 1 Year would result in 56.67% of your transactions generating a profit, with an average return of +13.57% per trade.
---